Glycozide M Forte Tablet is a combination oral antidiabetic medication containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose utilization. The synergistic effect of these two active ingredients helps in achieving optimal blood glucose levels in patients inadequately controlled by diet, exercise, or monotherapy. Glycozide M Forte is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is essential to monitor blood glucose levels regularly to adjust therapy accordingly and to minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Contraindications include severe renal or hepatic impairment, metabolic acidosis, and hypersensitivity to either component. Caution is advised in patients with cardiovascular disease or at risk of lactic acidosis. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Healthcare providers should individualize treatment and counsel patients on adherence and monitoring requirements.